• U.S. commercial launch of Salix® Coronary Anatomy platform completed
• Leadership transition to support commercial focus, with Co-Founder John Konstantopoulos appointed as CEO
• Major $0.6M five-year contract with Tanner Health in the U.S.

Artrya Limited (ASX: AYA), a medical technology company commercializing its Salix® AI-powered cloud platform, has released its Appendix 4C and quarterly activities report for the quarter ended 30 June 2025. Key highlights include the completion of the U.S. commercial launch of the Salix® Coronary Anatomy platform, a leadership transition with Co-Founder John Konstantopoulos appointed as CEO, and the signing of a major $0.6M five-year contract with Tanner Health in the U.S. The company also filed a 510(k) submission with the FDA for its Salix® Coronary Plaque module, which is expected to provide a reimbursement pathway under a Category I CPT code. Artrya is focused on successfully onboarding and expanding across its launch partners, expanding its product utility and revenue base, and implementing a staged commercial expansion in the U.S. based around its SAPPHIRE study centres. The company ended the quarter with $11.3M in cash and expects to receive an R&D tax rebate of $4.5M to $5M by the end of 2025.

Artrya expects to receive its first subscription revenues from the Salix® platform from the September quarter. The company also anticipates an R&D tax rebate of $4.5M to $5M by the end of 2025.

Artrya is focused on successfully onboarding and expanding across its launch partners, expanding its product utility and revenue base, and implementing a staged commercial expansion in the U.S. based around its SAPPHIRE study centres.